Maura Higgins breaks down in tears over facing fears on I’m A Celeb with Jane MooreLearn About the Importance of Commercial Pressure Washing With Todd's Pressure Washing

Rays will play 19 of their first 22 games at home as MLB switches series to avoid summer rain

NEWBURY: A couple of good ‘uns

Times News Network Ludhiana: Punjab Agricultural University (PAU), Ludhiana unveiled its newly-constructed Gate No 1 Road, now renamed Diamond Jubilee Road . This infrastructural enhancement, facilitated by the Punjab State Agricultural Marketing Board (PSAMB), has been designed and widened to accommodate footfall during events like Kisan Mela . The road was inaugurated by Harchand Singh Barsat, chairman, PSAMB, in the presence of the PAU vice-chancellor, Dr Satbir Singh Gosal and others. Barsat lauded the university for its exemplary role in revolutionising Indian agriculture. IPL 2025 mega auction IPL Auction 2025: Who went where and for how much IPL 2025: Complete list of players of each franchise Dr Gosal expressed his gratitude towards PSAMB for its support. He remarked, “The newly constructed road symbolises collaborative efforts of PAU and PSAMB in enhancing connectivity and accessibility for our stakeholders. This development will significantly improve logistics of events like the Kisan Mela, which draw hundreds of thousands of farmers annually. PAU remains committed to fostering agricultural excellence through robust infrastructure and outreach programs.” Dr Vishavjeet Singh Hans, chief engineer and Dr Rishi Indra Singh Gill, estate officer, PAU, said that the road was widened from 24 ft. to 50 ft., transforming it into a four-lane stretch with a 5-ft green belt on each side. Leading to Golden Jubilee Chowk, which was expanded from 20 ft to 30 ft, the road features a dedicated bicycle track, two security guard rooms, saucer drains for efficient drainage, and wheelchair accessibility. Additional enhancements include lane markings, zebra crossings, and solar-powered reflective cat eyes. We also published the following articles recently PAU youth fest: Agriculture College bags overall trophy Punjab Agricultural University's inter-college youth festival concluded with the College of Agriculture winning the overall trophy. Students showcased vibrant performances in traditional attire, including giddha and bhangra. The festival highlighted social issues like drug addiction and unemployment through dramatic enactments. New road construction begins in Narayanpur Road construction has begun in Abujhmarh, a remote area within Bastar division's LWE-affected districts, connecting Orchha and Aader. This project, under the Niyad Nellanar scheme, addresses local demands for better infrastructure. Narayanpur district officials and police aim to improve connectivity and development, responding to requests from residents in Sonpur, Garpa, and Kutul. Bicycle rider dies in road accident A cyclist tragically lost his life in a road accident near Mangaluru on Monday evening. Rakesh, the car driver, allegedly drove recklessly, hitting Ashraf's bicycle from behind. The impact threw Ashraf onto the road, causing severe head and chest injuries. Though rushed to a hospital in Thumbay and later transferred to Mangaluru, Ashraf succumbed to his injuries.

While You Were Sleeping: 5 stories you might have missed, Nov 27, 2024CHICAGO (AP) — (AP) — Des Watson led Loyola Chicago with 14 points and sealed the victory with a 3-pointer with 32 seconds remaining as the Ramblers knocked off South Florida 74-72 on Saturday. Watson shot 3 for 15 (2 for 8 from 3-point range) and 6 of 8 from the free-throw line for the Ramblers (8-0). Kymany Houinsou scored 12 points while finishing 5 of 7 from the floor and added seven rebounds and five assists. Jalen Quinn had 12 points and shot 4 of 8 from the field and 4 of 4 from the free-throw line. The Ramblers extended their winning streak to eight games. The Bulls (5-4) were led by Jayden Reid, who recorded 23 points, seven rebounds and four assists. Kasen Jennings added 13 points for South Florida. Jamille Reynolds had 12 points, 11 rebounds and four assists. Justin Moore scored six points in the first half and Loyola Chicago went into the break trailing 38-35. Watson scored a team-high nine points for Loyola Chicago in the second half, including their game-winning shot in the final minute. NEXT UP Loyola Chicago next plays Sunday against San Francisco at home, and South Florida will visit Utah State on Saturday. The Associated Press created this story using technology provided by Data Skrive and data from Sportradar .

There is optimism among Southern California defense contractors that the incoming presidential administration’s plans and policies will inject adrenaline into the local economy and generate hundreds of new jobs, especially with talk of strengthening the U.S. military. President-elect Donald Trump has publicly vowed to strengthen the country’s military by making it more efficient and through that find better ways to develop more defense products utilizing technology innovation. He has also said he will build up a larger naval fleet to compete with China. Just after winning the presidential election, Trump named Elon Musk and Vivek Ramaswamy, founder of a pharmaceutical company, as co-leaders of a government efficiency initiative focused on cutting bureaucracy and waste in government. Many smaller tech firms, some of which have relationships with Musk’s Space X and Tesla, are hopeful the initiative could give them an edge over bigger defense companies with huge budgets. “The new administration is very passionate about countering China and they recognize the ability for the U.S. to outcompete China that manufacturing is probably the most important thing to counter that threat,” said Chris Power, CEO and founder of Hadrian Automation, a company based in Torrance that runs automated factories building defense products. “We haven’t been talking about reindustrializing the country in the last 10 years. Now, the vice president, a lot of the policymakers are hellbent on figuring out how to reindustrialize the U.S., both by investing in the country and also by creating an even playing field with China.” Power, an Australian who lives in Hermosa Beach and started his company just three years ago, was among hundreds who attended the 11th annual Regean National Defense Forum held over the weekend at the Ronald Reagan Presidential Library in Simi Valley. The event is an opportunity for representatives of defense and technology companies to rub shoulders and exchange ideas with lawmakers, senior Department of Defense leadership, and foreign defense leaders in an environment away from the hubbub of the nation’s capital. Southern California is packed with hundreds of defense-oriented companies and continues to be a leader in military defense innovation. Commercial technology is also significant in the country’s national security approach. Because of that, the forum is also an opportunity for non-traditional companies to get a share of the spotlight and for startups like Hadrian Automation to get a chance to talk with people otherwise not in their sphere. This year’s forum, themed “Peace Through Strength in a Time of Transition,” included a day of back-to-back panel discussions. Key themes included what the new presidential administration would mean for defense, overcoming production and manufacturing constraints to build the future force, space capabilities and the space economy, modernizing defense capabilities, the next national defense strategy, and public opinion on national security after the election. During a discussion on force structure, resources and the next national defense strategy, panelists emphasized funding military needs going forward. Rep. Ken Calvert, R-Corona, who serves on the House Appropriations Defense Subcommittee, pressed the importance of passing the appropriation bills that fund military spending. “We need to get these bills done and give certainty to the military that they have the resources available in the Trump administration,” he said. “I know it’s difficult in an era where we have significant national debt, but nonetheless, our national security is at risk, and we need to move forward.” The uncertainty of the government’s appropriations process makes it difficult for the defense industry, “from a development perspective and a production perspective,” said Lawrence Culp Jr., chairman and CEO of GE Aerospace. “Without that clarity, it’s very hard to keep someone at task with all these stops and starts and the policy uncertainty of late – it’s very hard.” The smaller companies further down the supply chain bear a lot of the weight of uncertainty, he added. “When you talk about the small and medium-sized businesses that are part of that supply chain, the small companies we rely on for input, one, two, three tiers away, they’re at the end of the whip and they can’t really handle that, either operationally or financially.” Former Secretary of Defense Leon Panetta said at the forum that is where Trump needs to use his ability to generate enthusiasm among the public and make Americans aware of the nation’s dangers if it doesn’t have a strong military. “The American people really don’t understand how much of a threat we’re facing,” he said. “We have got to educate the American people on that. We haven’t had a president in the last years who has gone to the American people and gotten their support. It’s the only way you get leadership in Congress to pay attention and get the action you need.” The forum produces a survey each year on public perception of military defense, the last conducted just after the November election by a bipartisan research group. Of the 2,500 surveyed, 79% of respondents said they want the U.S. to spend more on national defense. At the same time, 61% said the military should be large enough to win two wars simultaneously; 49% said China poses the most significant threat, while 25% said Russia poses more of a threat. And, that’s where lawmakers such as Calvert think Southern California companies can have opportunities to become more successful. “Southern California is the intellectual capital of the world when it comes to national security innovation and manufacturing,” he said. “President Trump is committed to a strong military that is focused on the threats we face today and tomorrow. There’s no doubt in my mind that Southern California will continue to make a significant contribution to those important goals in the years ahead. There’s widespread agreement that we need to invest in our national security to remain the preeminent superpower in the world.” With a new administration coming in talking about cutting waste in government agencies while strengthening the country with a more targeted and effective military, local companies working with defense contractors and manufacturers are looking to the future with a hopeful eye. Brandon Tseng, a former Navy SEAL who co-founded Shield AI and attended the defense forum this year for the second time, said more government interest in smaller companies that produce military technology will help Shield AI create more jobs. The San Diego-based company, which employs 900 people, aims to protect service members and civilians with AI systems. It develops artificial intelligence-powered pilot systems, drones and technology for military operations. “I’m bullish on the defense tech ecosystem,” he said, adding that he’s excited about Trump’s inclusion in his administration of Musk, Ramaswamy and Stephen Feinberg, a private equity investor with interests in the defense industry, who Tseng calls problem-solvers. Related links “What I’m optimistic about is that you have these operators who have run companies, been in the trenches, solved problems, and know what it means to walk the walk, not just talk the talk,” Tseng said. “The administration is bullish on doing things more efficiently, more effectively; that’s what technology is about. I think you’re going to see it will be very helpful for a lot of defense tech companies.” And, it’s exactly the idea of manufacturing parts quickly and efficiently that Power, of Hadrian Automation in Torrance, believes will help reinspire U.S. manufacturing, which he believes is the basis of a strong national defense. With his company, he hopes to inspire many young, smart people to want to get back into manufacturing – but in a more modern way that uses software to improve the manufacturing process and make it more efficient and effective. “U.S. power is based on the dollar,” he said. “The dollar is based on military might, which is really based on industrial power. We shot ourselves in the foot as a country by outsourcing our industrial power to China. That took away all the manufacturing skillsets, manufacturing technology, and a lot of jobs. For the last 25 years, we’ve treated China like a partner, but they have been subsidizing aggressively their manufacturing base specifically to gut our industrial power as a country.” At the same time the general public’s interest in manufacturing has dipped, he argued, with more people in the 1980s and ’90s choosing a four-year degree as the way to a successful future and a middle class that commands relatively high wages. “If you want manufacturing in America, the only way to do it is to build software factories that give the American workforce a productivity advantage so we can scale and use a new workforce instead of a legacy,” he said. “And if we want to be cost-competitive globally and efficient, we either have to pay everyone a very small amount or give the American workforce the 10x advantage with American software engineering and robotics.” Power sees Trump’s focus on empowering industrialization as having a huge impact on jobs. He plans to open two new facilities in the next year. “The faster we scale, the more jobs we provide,” he said. “And they’re better and more exciting jobs.” Related ArticlesThe 49ers' playoff hopes are still teetering even after get-right game against the Bears

What happens when 'The Simpsons' join 'Monday Night Football'? Find out during Bengals-Cowboys

No. 7 Mercer stages 4th-quarter comeback to top No. 10 Rhode Island 17-10, advances to FCS semifinal

The Mangaluru city police are searching for a person accused of drugging and sexually assaulting a woman from Mangaluru. He is also accused of raping the woman several times by threating to release video clippings of the sexual assault on social media. In a complaint filed recently at the Mangaluru East police station, the victim said she befriended the accused on July 21 when he helped her in repairing her car that had broken down on a city road. He introduced himself to her as Mohammed Shafin. On August 1, he helped in repairing the refrigerator in her house. On that day, he offered her juice mixed with a sedative. When she was asleep he raped her. He threatened to release the video of the rape and sexully assaulted her several times later. He had taken her car to his house, the complaint said. When she went to his house in Deralakatte on October 25, Shafin’s brother Mohammed Shiyab threatened to sexually assault her. When he attempted to touch her inappropriately, she ran out of the the house. On October 27 night, Shafin came to her house and stole ₹62,000 from her bag when she was cooking food., she stated in the complaint. On November 26, the Mangaluru East police registered her complaint for offence punishable under Sections 3 (5), 64, 76, 331, 351(3), 305(a) of Bharatiya Nyaya Sanhita and Section 67(a) of Information Technology Act Published - December 08, 2024 02:00 am IST Copy link Email Facebook Twitter Telegram LinkedIn WhatsApp RedditGraeme Shinnie takes jab at his Aberdeen cynics as skipper points to Harry Kane exampleMan on Trial in Ole Miss Student's Death Lied to Investigators, Police Chief Says

All Three Patients Treated in First Dose Cohort Administered Fludarabine-free Conditioning and Show Rapid, Deep, and Sustained B-cell Depletion with Favorable Safety Profile First Patient to Reach 6-Month Follow-up Remains in DORIS Clinical Remission and Free of All Immunosuppressive Therapies Company Plans to Initiate Dose Expansion at First Dose Level of 360M Cells SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today presented new clinical and translational data from the Company’s FT819 Phase 1 Autoimmunity study for moderate-to-severe systemic lupus erythematosus (SLE) at the American Society of Hematology (ASH) Annual Meeting being held in San Diego, CA. The first three study patients, each of whom presented with active lupus nephritis (LN) despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning followed by a single dose of FT819 at 360 million cells. There were no dose-limiting toxicities (DLTs), no events of any grade of cytokine release syndrome (CRS), immune effector-cell associated neurotoxicity syndrome (ICANS), or graft-versus-host disease (GvHD), and rapid, deep, and sustained elimination of CD19+ B cells in the periphery was observed during the first month of treatment. FT819 is the Company’s off-the-shelf, CD19-targeted, 1XX CAR T-cell product candidate comprised of CD8αβ+ T cells with a memory phenotype and high CXCR4 expression to promote tissue trafficking. “We continue to be very pleased with early clinical observations of fludarabine-free conditioning and FT819 off-the-shelf, CAR T-cell therapy in patients with moderate-to-severe SLE. The remarkable experience of the first patient treated in April is ongoing, as the patient remains on-study in drug-free clinical remission. In addition, the initial clinical and translational data from the two additional patients treated at the first dose level continue to support the potential for disease transformation,” said Bob Valamehr, President of Research and Development of Fate Therapeutics. “We are now initiating dose expansion at this first dose level to accelerate development, and are also escalating dose based on the favorable safety profile observed. In addition, I am pleased to announce that the first patient has now been treated with FT819 as an add-on to maintenance therapy without conditioning chemotherapy. We believe our therapeutic approach is highly-differentiated and has the potential to transform disease outcomes without requiring patient apheresis, discontinuation of maintenance therapy, intense conditioning chemotherapy, and extended hospitalization.” FT819 Phase 1 Autoimmunity Study The ongoing multi-center, Phase 1 clinical trial for patients with moderate-to-severe SLE is designed to evaluate the safety, pharmacokinetics, and anti-B cell activity of FT819 (NCT06308978). The first three patients, all of whom presented with active LN despite having been treated with multiple standard-of-care therapies, received fludarabine-free conditioning consisting of either cyclophosphamide alone or bendamustine alone, followed by a single dose of FT819 at 360 million cells. In all three patients, FT819 was detected in the peripheral blood and rapid, deep, and sustained elimination of CD19+ B cells in the periphery was observed during the first month of treatment. All three patients remain on-study, and there have been no DLTs and no events of any grade of CRS, ICANS, or GvHD. Based on these clinical observations, the Company is initiating dose expansion in up to 10 patients at this first dose level, and is also escalating dose to 720 million cells. The Company’s FT819 Phase 1 Autoimmunity study also includes a second treatment arm to assess the safety, pharmacokinetics, and anti-B cell activity of a single dose of FT819 as an add-on to maintenance therapy without conditioning chemotherapy in patients with SLE. The first patient has now been treated in this second arm, which is being conducted in parallel with the study’s conditioning arm. FT819 Patient 1 Case Study The first patient treated in the Phase 1 Autoimmunity study presented with active LN and severe disease, which was marked by renal BILAG A (British Isles Lupus Assessment Group) disease activity score based on biopsy, SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index) score of 20, FACIT-Fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue) score of 33 (range 0-52, where a score of 52 indicates no fatigue) and PGA (Physician Global Assessment) score of 2.5 (where a score of 3 indicates most severe activity). Following administration of fludarabine-free conditioning and treatment with a single dose of FT819 at 360 million cells, the patient was discharged from the hospital without notable adverse events (AEs) after a protocol-required three-day stay. Rapid elimination of CD19+ B cells in the periphery was observed following treatment, and B-cell recovery by Month 3 was predominantly comprised of naïve, non-class switched B cells with near-complete elimination of switched memory B cells and deep depletion of plasmablasts, indicative of an immune reset. The patient reported that her debilitating fatigue had entirely resolved without further treatment, and treatment with methylprednisolone was discontinued at Month 3. The patient achieved DORIS (definition of remission in SLE) clinical remission, including with resolution of arthritis and active urinary sediment and with a substantial reduction in proteinuria, as of Month 6 follow-up. The patient continues on-study, in DORIS clinical remission, and remains free of all immunosuppressive therapy. iPSC-derived CAR T-cell Product Platform The Company also highlighted the scientific progress of its proprietary iPSC-derived CAR T-cell product platform at the ASH Annual Meeting. In an oral presentation entitled “ Off-the-shelf Product Candidate Incorporates Novel Sword & Shield Technology Designed to Promote Functional Persistence without Conditioning Chemotherapy ”, the Company compared its novel Sword & Shield technology, which utilizes a 4-1BB-targeted CAR (ADR) alongside the complete knock-out of CD58 (CD58KO) to both target and evade host alloreactive immune cells, to other host immune evasion strategies. In preclinical studies of allogeneic models, the Company showed that its Sword and Shield Technology specifically engaged with alloreactive T cells and supported functional persistence while avoiding the killing of general host T cells and activated anti-tumor T cells. This unique observation was not seen with other approaches that are either too broad and undesirably eliminate most of the host immune system or have limited coverage and cannot adequately protect the allogeneic cell product. In a second presentation entitled “ Development of Induced Pluripotent Stem Cell-Derived T Cells Exhibiting Phenotypic and Functional Attributes of Primary CAR T Cells ”, the Company conducted a series of high-resolution analyses to show stimulated iPSC-derived T cells elicit primary T-cell like activation, proliferation, transcriptional and functional program engagement, and iPSC-derived CAR T cells uniquely emulate antigen-mediated response similar to primary-derived autologous CAR T cells. About Fate Therapeutics’ iPSC Product Platform Human induced pluripotent stem cells (iPSCs) possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s proprietary iPSC product platform combines multiplexed-engineering of human iPSCs with single-cell selection to create clonal master iPSC lines. Analogous to master cell lines used to mass produce biopharmaceutical drug products such as monoclonal antibodies, the Company utilizes its clonal master iPSC lines as a starting cell source to manufacture engineered cell products which are well-defined and uniform in composition, can be stored in inventory for off-the-shelf availability, can be combined and administered with other therapies, and can potentially reach a broad patient population. As a result, the Company’s platform is uniquely designed to overcome numerous limitations associated with the manufacture of cell therapies using patient- or donor-sourced cells. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 500 issued patents and 500 pending patent applications. About Fate Therapeutics, Inc. Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com . Forward-Looking Statements This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the safety and therapeutic potential of the Company’s iPSC-derived CAR T-cell product candidates, including FT819, the advancement of and plans related to the Company's product candidates, clinical studies and preclinical research and development programs, the Company’s progress, plans and timelines for the clinical investigation of its product candidates, including the expected clinical development plans for FT819, the initiation and continuation of enrollment in the Company’s clinical trials, the initiation of additional clinical trials and additional dose cohorts in ongoing clinical trials of the Company’s product candidates, the timing and availability of data from the Company’s clinical trials, the therapeutic and market potential of the Company’s research and development programs and product candidates, the Company’s clinical and product development strategy, and the Company’s expectations regarding progress, plans, and timelines. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that the Company’s research and development programs and product candidates, including those product candidates in clinical investigation, may not demonstrate the requisite safety, efficacy, or other attributes to warrant further development or to achieve regulatory approval, the risk that results observed in prior studies of the Company’s product candidates, including preclinical studies and clinical trials, will not be observed in ongoing or future studies involving these product candidates, the risk of a delay or difficulties in the initiation and conduct of, or enrollment of patients in, any clinical trials, the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, changes in the therapeutic, regulatory, or competitive landscape for which the Company’s product candidates are being developed, the amount and type of data to be generated or otherwise to support regulatory approval, difficulties or delays in patient enrollment and continuation in the Company’s ongoing and planned clinical trials, difficulties or delays in manufacturing or supplying the Company’s product candidates for clinical testing, failure to demonstrate that a product candidate has the requisite safety, efficacy, or other attributes to warrant further development, and any adverse events or other negative results that may be observed during preclinical or clinical development), and the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Company’s periodic filings with the Securities and Exchange Commission, including but not limited to the Company’s most recently filed periodic report, and from time to time in the Company’s press releases and other investor communications. Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise. Contact: Christina Tartaglia Precision AQ 212.362.1200 christina.tartaglia@precisionaq.com

EVTOLs Remain Grounded As Dreams Of Jetsons Lifestyle Doppler Into Future

NEW YORK (AP) — Major League Baseball switched a pair of series involving the Tampa Bay Rays to the first two months of the season in an attempt to avoid summer rain at open-air Steinbrenner Field, their temporary home following damage to Tropicana Field. Tampa Bay is scheduled to play 19 of its first 22 games at home and 37 of 54 through May 28, then play 64 of its last 108 games on the road. The Rays are home for eight games each in July and August. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.ESPN's "College GameDay" has become a staple during each college football season. Lee Corso has become a cornerstone of the program since the show began in 1987. However, with Corso nearing the age of 90, his future with "College GameDay" is up in the air. Corso has missed a few weeks of the show due to health issues, so his time on the set could be coming to an end. Recently, ESPN President Burke Magnus discussed Corso's future : “I think we’re going to do what we’ve done now for a couple of years running, which is we’re gonna have a conversation with him after the season and see where things are,” Magnus said. Andrew Wevers-Imagn Images Magnus said they will take time to "figure out" what everyone wants to do after the season ends. Nonetheless, the future of Corso on "College GameDay" is a big question mark, and college football fans have mixed feelings about it. "As far as I’m concerned, Corso and @DickieV should stay at ESPN as long as they want to. They have done so much for college sports and deserve to leave on their terms. They are both legends!" one fan said . "As long as he’s breathing air, I want him on set," said another . "Coach is doing just fine," said another . On the other hand, some fans want Corso to retire for his good. "Lee Corso is an icon on College GameDay but it is time for him to retire. I think it would be wonderful to have the first show of next season, the light on content Week 0 show, be a celebration of and farewell for him. It gives the fan base a chance to properly say thank you," one fan replied. "Please let him retire," wrote another. "Let the man retire. It looks so sad seeing him there and can barely move," said another fan . Corso will be 90 years old when the 2025 college football season begins, so it wouldn't be surprising to see this year be his final run on the "College GameDay" set. However, those conversations will be had after the season ends. Either way, college football fans have mixed feelings about Corso's unclear future. Related: ESPN President Reveals Plans For Lee Corso’s 'College GameDay' Future

Former MP Fidele Mitsindo passes on aged 58The 49ers' playoff hopes are still teetering even after get-right game against the Bears